VBVadim Yur'EVich Balabaniyan

Vadim Yur'EVich Balabaniyan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vadim Yur'EVich Balabaniyan has a total of 149 co-authors. Here are the top co-authors by number of shared publications:

  • В. Ю. Балабаньян

    Федеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Министерства здравоохранения Российской Федерации (ФГАОУ ВО РНИМУ им. Н. И. Пирогова Минздрава России)

    15 shared publications
  • Nikita S. Popov

    Tver State Medical University

    11 shared publications
  • Mikhail S. Baranov

    Laboratory of Medicinal Substances Chemistry, Institute of Translational Medicine, Pirogov Russian National Research Medical University, Ostrovitianova 1, Moscow 117513, Russia

    8 shared publications
  • Vladimir Sergeevich Popov

    Lomonosov Moscow State University

    8 shared publications
  • Ivan N. Myasnyanko

    Laboratory of Medicinal Substances Chemistry, Institute of Translational Medicine, Pirogov Russian National Research Medical University, Ostrovitianova 1, Moscow 117513, Russia

    7 shared publications
  • Valeriy Gennadievich Makarov

    Research and Manufacturing Company “HOME OF PHARMACY

    7 shared publications

Latest Publications

  • Open Access

    Pharmacokinetics and Effect of Novel Sydnonimine on NO and cGMP Accumulation In Vivo

    by Nikita S. Popov, Dmitry A. Gavrilenko, Dmitry O. Tsypyshev, Vladimir V. Turovtsev, Mikhail S. Baranov, Dmitry S. Ivanov, Ivan N. Myasnyanko, Diana E. Kaurova, Sergey A. Filatov, Yulia V. Vakhitova, et al.

    Background: Sydnonimines are mesoionic heterocyclic NO donors with vasodilatory activity. Molsidomine, a clinically approved sydnonimine, has limited blood–brain barrier (BBB) penetration, restricting its use for cerebrovascular disorders. This study characterizes the lead compound BBP2023 as a potential NO donor with putative cerebral action. Methods: In silico ADME profiling (RDKit) of 14 sydnonimines, rat pharmacokinetics of oral BBP2023 (11 mg/kg) vs. molsidomine (10.4 mg/kg), HPLC-MS/MS of NO/cGMP, and docking against four human sGC PDB entries were performed. Results: BBP2023 showed high lipophilicity (logP 1.58), low TPSA (69.78 Å2) and predicted high BBB permeability. After oral dosing, BBP2023 was rapidly absorbed (plasma Tmax 0.17 h, Cmax 389 ng/mL, AUC_last 235 h·ng/mL) and extensively distributed, with highest exposure in liver (AUC_last 1457 h·ng/mL, ~6-fold plasma), indicating primary hepatic metabolism. Brain penetration was confirmed (fr = 1.39, MRT 3.01 h). The active metabolite BBP2023 A appeared later (plasma Tmax 1.00 h, Cmax 22 ng/mL) and accumulated in the lungs (fr = 25.31, AUC_last 1569 h·ng/mL) and brain (fr = 3.65, MRT 4.16 h). Compared with molsidomine, BBP2023 achieved higher brain exposure (availability 1.4 vs. 0.2, Cmax 852.5 vs. 142.3 pmol/mL) and faster brain Tmax (≤0.25 h vs. 1 h). BBP2023 significantly increased NO and cGMP in the brain (131.00 ± 26.39 nM/g and 1070.83 ± 92.04 pM/g, respectively), whereas molsidomine predominantly elevated heart NO. Docking and MM-GBSA calculations suggested possible interactions of BBP2023 and its metabolites with the sGC stimulator site and associated the intact sydnonimine ring with more favorable calculated scores. Conclusions: BBP2023 acts as a NO donor with favorable pharmacokinetics, effective BBB penetration, and brain NO/cGMP accumulation, supporting its further development for cerebrovascular disorders.

  • Open Access

    Development and validation of HPLC-MS/MS technique for the quantitative determination of a new derivative of sydnonymine and its metabolites in rabbit plasma

    by N. S. Popov, D. A. Gavrilenko, M. S. Baranov, D. E. Kaurova, I. N. Myasnyanko, I. A. Solokha, V. Yu. Balabanyan, В. Ю. Балабаньян

    Introduction. BBP2023 is a new drug candidate of the sydnonymine group with cerebral vasodilating activity and procognitive properties. The pharmacological effects of BBP2023 are due to the presence of active metabolites. To conduct pharmacokinetic studies at the preclinical stage, it is necessary to develop a bioanalytical method for the determination of BBP2023 and its metabolites in rabbit blood plasma. Aim. Development and validation of a chromatography-mass spectrometric method for the quantitative determination of a new derivative of sydnonymine and its metabolites in rabbit blood plasma. Materials and methods. Quantitative determination of BBP2023 in rabbit blood plasma was performed by HPLC-MS/MS. The biomaterial sample preparation was based on the method of protein precipitation with methanol. Chromatographic separation was performed with a mixture of deionized water and acetonitrile in a gradient mode on a ZORBAX Eclipse XDB-C18 analytical column (4.6 × 50 mm, 5 μm) using an Agilent 1260 Infinity II chromatograph. Detection was performed in the MRM mode using an AB Sciex QTRAP 3200 MD mass spectrometer. N-(ethoxycarbonyl)-3-(4-methylpentan-2-yl)sydnonymine was used as the internal standard. Results and discussion. The method for sample preparation of rabbit blood plasma has been developed, optimal conditions for chromatography and detection of the studied compound and its metabolites have been selected. The bioanalytical method has been validated according to the following parameters: selectivity, matrix effect, recovery rate, carry-over effect, linearity of the calibration range, lower limit of quantitative determination, intraand inter-run accuracy and precision, as well as stability of analytes and the internal standard at the analysis stages. Conclusion. A method for the quantitative determination of a new derivative of sydnonymine BBP2023 and its metabolites in rabbit blood plasma using HPLC-MS/MS has been developed and validated. The confirmed analytical ranges for BBP2023, BBP2023 A and BBP2023 C were 5.0–500.0 ng/ml (5.0–1000.0 ng/ml for geranamine). The method was used in the analytical part of the preclinical pharmacokinetic study of BBP2023 in rabbits.

  • Open Access

    Study of the pharmacokinetics of a new sidnonymine derivative in mice with intragastric administration

    by N. S. Popov, D. A. Gavrilenko, M. S. Baranov, D. S. Kaurova, I. N. Myasnyanko, D. S. Ivanov, I. Yu. Ilnitskaya, V. Yu. Balabanyan, В. Ю. Балабаньян

    Relevance. BBP2023 is a new drug candidate of the sydnonimine group, possessing predominantly central vasodilating activity. Objective. To study the pharmacokinetics of the drug candidate BBP2023 in mice after intragastric administration, including an assessment of distribution to organs and tissues. Materials and methods. Experiments were performed on 102 outbred male mice. The animals received a single intragastric dose of BBP2023 at 22.0 mg/kg as an oil emulsion. The total duration of the experiment was 72 hours, during which the animals were euthanized by decapitation at specific time points. Plasma was obtained from blood; homogenates were prepared from internal organs (liver, kidneys, heart, lungs, brain, spleen, muscles, omentum). These were analyzed for the quantitative content of BBP2023 and its metabolites using a previously developed and validated HPLC-MS/MS method. The main pharmacokinetic parameters were calculated using a non-compartmental method. Results. After intragastric administration, BBP2023 was detected in all studied organs and tissues. The time to reach the maximum concentration (0.58 μg/ml) in plasma was 15 minutes, and the elimination half-life was about 7.9 hours. The highest distribution found was to the liver (fr = 2.83), lungs (fr = 1.58), and omentum (fr = 2.62). The minimum value of the elimination rate constant, excluding blood plasma, was observed in brain tissues. The active metabolite BBP2023 A was primarily localized in the kidneys (fr = 16.85) and liver (fr = 4.61). The time to reach the maximum concentration in all organs and tissues ranged from 15 to 45 minutes. Conclusion. The results of the study established that the sydnonimine group drug candidate BBP2023, as well as its active metabolite (BBP2023 A), are detected in mouse brain tissues, which contributes to the realization of cerebral vasodilating activity.


  • Open Access

    Study of the pharmacokinetics of a new sidnonymine derivative in rabbits with various routes of administration

    by N. S. Popov, D. A. Gavrilenko, M. S. Baranov, D. E. Kaurova, I. N. Myasnyanko, V. Yu. Balabanyan, В. Ю. Балабаньян

    Relevance. The search for vasodilating agents that predominantly accumulate in brain tissues is an urgent task. One of the drug candidates with cerebral vasodilating activity is BBP2023 a derivative of sydnonymine. Objective. A comparative assessment of the pharmacokinetics of BBP2023 in rabbits after a single administration via different routes. Methods. Experiments were performed using a crossover design on 8 rabbits. The rabbits received a single dose of BBP2023 at 2.0 mg/kg as an oil emulsion intragastrically and rectally, and as an aqueous DMSO solution intravenously and intramuscularly. Blood samples were collected from the marginal ear vein at specific time points. The quantitative determination of BBP2023 and its metabolites in blood plasma was performed using HPLC-MS/MS. Results. It was found that the highest bioavailability values are achieved with intramuscular administration (97.4 %). With intragastric and rectal administration, this indicator averaged 46.1 and 15.3 %, respectively. The maximum concentration of BBP2023 in blood plasma is reached on average 5 minutes after intragastric administration and averages 0.620 μg/ml; the half-life value averages 1 hour. The maximum concentration of the active metabolite BBP2023 A in blood plasma after intragastric administration is detected on average after 25 minutes and is 0.076 μg/ml. Conclusion. The pharmacokinetics of the active pharmaceutical substance of drug candidate BBP2023 was studied in rabbits. The results obtained were used for the subsequent selection of the optimal finished dosage form and route of administration.


  • QUANTITATIVE DETERMINATION OF A NEW SIDNONYMINE DERIVATIVE IN BLOOD PLASMA AND ORGANS OF MICE USING HPLC-MS/MS

    by N. Popov, D. Gavrilenko, M. Baranov, D. Kaurova, I. Myasnyanko, D. Ivanov, V. Balabanyan

    Introduction. Sydnonymines are a class of heterocyclic chemical compounds with a wide range of biological activity and promising in terms of the search and development of new drugs. One of these compounds is the candidate molecule BBP2023, N-(ethoxycarbonyl)-3-(4-methylhexane-2-yl)sydnonymine. It has been determined that BBP2023 accumulates in the brain tissues of laboratory animals and causes a cerebral vasodilating effect, which makes it possible to consider this compound as a promising drug used to treat cerebral circulatory disorders. Goal – development and validation of a bioanalytical method for the determination of a new sidnonymine derivative in various tissues of laboratory mice with a view to further application in experimental pharmacokinetic research. Material and methods. Quantitation of BBP2023 in blood plasma and organ homogenates of mice was performed by HPLC-MS/MS. The technique of precipitation of proteins with methanol was used as the basis for biomaterial sample preparation. Chromatographic separation was performed with a mixture of deionized water and acetonitrile in a gradient mode on a Zorbax Eclipse XDB-C18 4,6×50 mm, 5 µm column. Detection was performed in the MRM mode. Results. As a result of the experiment, a technique for sample preparation of biological material of mice was developed, optimal conditions for chromatography and detection of the studied compound were selected. The bioanalytical technique has been validated according to the following parameters: selectivity, matrix effect, recovery rate, carry-over, linearity of the calibration range, lower limit of quantitative determination, intra- and inter-run accuracy and precision, dilution factor, as well as stability of the analyte and the internal standard at the analysis stages. Conclusion. As a result of the experiment, a method was developed for the quantitative determination of a new derivative of sydnonymine BBP2023 in blood plasma and internal organs of mice. The analytical range of the method ranged from 5 to 5,000 ng/ml for blood plasma and from 25 to 25,000 ng/g for liver, kidneys, heart, lungs, brain, spleen, skeletal muscles and adipose tissue. The bioanalytical method fully meets the validation requirements and can be used to perform the analytical part of an experimental study of the pharmacokinetics of BBP2023, including an assessment of the distribution of the studied compound across organs and tissues.

  • Open Access

    Study of the biotransformation of a new sydnonimine derivative with predominant cerebral vasodilatory activity

    by Nikita S. Popov, Dmitry A. Gavrilenko, Roman D. Pavlov, Mikhail S. Baranov, Diana E. Kaurova, Ivan N. Myasnyanko, Dmitry S. Ivanov, Vadim Yu. Balabanyan

    Introduction: Sydnonimines are a promising group of drugs for development of novel substances with predominant cerebral vasodilatory activity. One of them is experimental compound with laboratory code BBP20233. The mechanism of action of BBP2023 compound is tied to its metabolites. This study aims for identification of biotransformation products of BBP2023 using HPLC-MS/MS method. Materials and Methods: Identification of BBP2023 biotransformation products was performed in male rats and male rabbits after intragastric administration of BBP2023 in form of oil emulsion. Blood samples were collected before and 1 and 8 hours after administration. Urine samples from rats were collected before and 24 hours after administration. Additionally, complete liver isolation was performed in another group of rats to investigate liver’s role in BBP2023 metabolism. Identification of products was performed using HPLC-MS/MS method as well as UHR-TOF method. Results and Discussion: Analysis of rat plasma samples collected 1 hour after administration revealed the presence of parent compound, active metabolite SIN, geranamine and various isomers of OH-derivatives. Analysis of rat urine samples collected 24 hours after administration showed the presence of glucuronic acid conjugates of SIN and parent compound. Similar results were obtained from rabbit plasma samples, although with less variety of hydroxylated derivative isomers. Conclusion: Investigated features of BBP2023 biotransformation require detailed analysis of pharmacokinetics for both BBP2023 and its metabolites to determine their role in therapeutic effect and possible adverse effects.


  • Open Access

    Evaluation of the therapeutic effects of fonturacetam in the chronic unpredictable mild stress (CUMS) model in rats

    by HOME OF PHARMACY Research and Manufacturing Company, Sona S. Arutyunyan, Elena V. Shekunova, Natalia M. Faustova, Vladimir A. Kashkin, Marina N. Makarova, Valery G. Makarov, Marat F. Fazylov, Gelespon, Vadim Yu. Balabanyan

    Background: Chronic stress can lead to adverse consequences such as occupational burnout ...

  • Open Access

    Safety Profile Evaluation of an Original Mesenchymal Stromal Cell Secretome-Based Medicinal Product after Intratesticular Injection in Rabbits

    by А. О. Monakova, V. Yu. Balabanyan, V. A. Vavilova, N. A. Basalova, V. S. Popov, Zh. A. Akopyan, A. Yu. Efimenko

    INTRODUCTION. This work is a continuation of the studies of an original biological product based on the secretome of human mesenchymal stromal cells (MSCs) and intended for the restoration of spermatogenesis and fertility. To ensure the safety of the product, it is necessary to conduct preclinical studies in two types of animals, including rodents (the results of rodent studies were presented earlier) and non-rodents.AIM. This study aimed to investigate the systemic toxicity, safety pharmacology, pyrogenicity, immunotoxicity, reproductive toxicity, and local tolerance of the original MSC secretome product in mature rabbits after two injections under the tunica albuginea of the testes.MATERIALS AND METHODS. The study was conducted in 50 male Soviet chinchilla rabbits (5 groups of 10 animals). The lyophilised MSC secretome product (MediReg) was reconstituted, mixed with collagen gel (Applicoll), and administered to rabbits subalbugineally on days 1 and 28 at a dose equal to the therapeutic dose (≥0.76 ng of vascular endothelial growth factor (VEGF)), 1.5 therapeutic doses (≥1.14 ng of VEGF), or 2.5 therapeutic doses (≥1.9 ng of VEGF). The control groups included intact rabbits and rabbits that received Applicoll mixed with water for injection. The animals were assessed in terms of their clinical condition, body temperature, electrocardiogram changes, heart and respiratory rates, blood pressure, modified Irwin test results, urinalysis findings, blood counts and biochemistry, haemostasis parameters, arterial blood gas measurements, and spermogram changes. Further, the animals were necropsied, and selected organs were weighed and subjected to histopathology. The follow-up period was 60 days.RESULTS. On day 3, the groups receiving 1.5 and 2.5 therapeutic doses of the medicinal product demonstrated a significant decrease in prothrombin time; however, only the placebo group still had decreased prothrombin time levels during the follow-up period. The histological examination revealed occasional splitting areas in the intertubular connective tissue with the formation of cavities filled with a loose substance with pronounced eosinophilic staining and deformation of the tubules along the walls of the cavities as a result of compression in 1–2 of 5 (20–40%) rabbits in all groups that received either the medicinal product or placebo. This was probably caused by mechanical compression of the tubules by the administration of large volumes of substances. In the placebo group, 2 of 5 (40%) animals had a transient increase in the size of the vesicular glands; the lobules were markedly expanded and contained a transparent secretion. The histological appearance of the vesicular glands was normal.CONCLUSIONS. When administered twice under the tunica albuginea of the testes of rabbits, the medicinal product comprising the MSC secretome and the Applicoll collagen gel carrier has an acceptable safety profile.


  • COMPARATIVE CHARACTERISTICS OF THE QUANTITATIVE CONTENT OF POLYPRENOLS IN SUBSTANCES DERIVED FROM GINKGO BILOBA L. AND PICEA ABIES L.

    by А.а. Antipina, N.S. Popov, М.S. Baranov, I.N. Myasnyanko, S.V. Savintsev, V.Yu. Balabanyan

    Introduction. Polyprenols are known as a class of natural long-chain isoprenoid alcohols, which are fat-soluble antioxidants and natural bioregulators that directly participate in the synthesis of glycoproteins of cell membranes. Their hepatoprotective activity is proven, as well as other types of their pharmacological effects are known, which is the reason of significant interest in these substances as a promising medicinal product. The main sources of polyprenols are coniferous trees (various types of spruce (Picea spp.), fir (Abies spp.), pine (Pinus spp.)), as well as Ginkgo biloba L.). Prepar-ative isolation of polyprenols from plants is carried out by extraction based on the difference in solubility in two or more organic solvents. Aim. Identification and comparative quantitative assessment of polyprenols in substances derived from Ginkgo biloba L. and Picea abies L. according to the author’s method in Savintsev’s laboratory. Material and methods. Identification of polyprenols in substances was carried out using proton nuclear magnetic resonance (NMR) spectroscopy, Fourier-transform infrared spectroscopy (FTIR), mass spectrometry (MS), and high-performance liquid chromatography (HPLC). The quantitative content of polyprenols was determined using HPLC-MS, a triple quadrupole mass spectrometer was used as a detector. Results. Polyprenols in substances were identified by 1H NMR spectroscopy, IR spectroscopy, mass spectrometry and high-performance liquid chro-matography. Using HPLC-MS, the quantitative content of C70 – C100 polyprenols in samples of Ginkgo biloba L. and Picea abies L. was found to be 76% and 95% on average, respectively. Conclusions. The predominance of shorter polyprenols in the substance of Picea abies L. compared to the substance of Ginkgo biloba L. can be sug-gested based on the results of comparative characteristics of the chromatographic peaks expression and the results of 1H NMR spectroscopy. The regulatory documentation can be prepared based on the results of this study for subsequent state registration of pharma-ceutical substances and medicines of polyprenols derived from Ginkgo biloba L. and Picea abies L.


  • Open Access

    Development of a method for quantitative determination of nitric oxide (NO) in rat tissues based on high-performance liquid chromatography and mass spectrometry

    by N. S. Popov, D. A. Gavrilenko, M. S. Baranov, V. Yu. Balabanyan, В. Ю. Балабаньян

    A quantitative assessment of nitric oxide (NO) production in body tissues is an urgent problem in pharmacology and biochemistry. The study of physiological processes occurring with the participation of NO, as well as the metabolism and pharmacodynamics of pharmacological agents from the group of NO donors, requires the introduction of accurate and reproducible methods for the quantitative determination of this metabolite in biological media.The aim of the study was to develop the HPLC-MS/MS methods for the quantitative determination of NO in various tissues of rats.Materials and methods. The indirect NO quantification was based on estimation of the level of more stable metabolites: nitrites and nitrates extracted from rat tissues by homogenization with water. The reduction of nitrates to nitrites was carried out using nitrate reductase. The derivatization of nitrites was based on a reaction with Griess reagent. The resulting azo dye was determined by HPLC-MS/MS using an Agilent InfinityLab Poroshell 120 EC-C18 4.6×100 mm, 2.7 μm analytical column. The total chromatographic analysis time was 12 minutes, and the analyte retention time was 6.1 minutes. The analytical range of the method was 0.1–100.0 nmol (in terms of nitrite) per 1 ml of plasma or tissue homogenate.Results. The developed a bioanalytical method was validated according to the following parameters: a selectivity, a matrix effect, a recovery degree, a sample transfer, an analytical range linearity, a lower limit of quantification (LLOQ), an intra- and inter-assay accuracy and precision, and a stability at all the stages of the analysis. To test the method, the NO content in the plasma, brain, heart, aorta and lungs of rats was determined.Conclusion. The developed bioanalytical HPLC-MS/MS methods fully meets the validation requirements. The metrological characteristics of the technique make it possible to highly accurately estimate the NO production in various tissues of rats, which is undoubtedly relevant and in demand in the study of pathological processes as well as the mechanism of action of pharmacological agents from the group of NO donors.